利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.049 秒)

    Antibody Constant Region Variant
    1.
    发明申请
    Antibody Constant Region Variant 审中-公开
    抗体恒定区变体

    公开(公告)号：US20120071634A1

    公开(公告)日：2012-03-22

    申请号：US13257145

    申请日：2010-03-19

    申请人： Tomoyuki Igawa ,  Taichi Kuramochi ,  Atsuhiko Maeda ,  Hirotake Shiraiwa

    发明人： Tomoyuki Igawa ,  Taichi Kuramochi ,  Atsuhiko Maeda ,  Hirotake Shiraiwa

    IPC分类号： C07K16/18

    CPC分类号： C07K16/00 ,  C07K16/2866 ,  C07K16/2875 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/528 ,  C07K2317/53 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

    摘要： By altering amino acid sequences, the present inventors successfully produced constant regions that can confer antibodies with particularly favorable properties for pharmaceutical agents. When used to produce antibodies, the altered constant regions produced according to the present invention significantly reduce heterogeneity. Specifically, the antibody homogeneity can be achieved by using antibody heavy chain and light chain constant regions introduced with alterations provided by the present invention. More specifically, the alterations can prevent the loss of homogeneity of antibody molecules due to disulfide bond differences in the heavy chain. Furthermore, in a preferred embodiment, the present invention can improve antibody pharmacokinetics as well as prevent the loss of homogeneity due to C-terminal deletion in antibody constant region.

    摘要翻译： 通过改变氨基酸序列，本发明人成功地制备了可赋予具有特别有利于药剂特性的抗体的恒定区域。 当用于产生抗体时，根据本发明产生的改变的恒定区域显着降低异质性。 具体而言，抗体均一性可以通过使用由本发明提供的改变引入的抗体重链和轻链恒定区来实现。 更具体地，改变可以防止由于重链中的二硫键差异导致的抗体分子的均匀性的丧失。 此外，在优选的实施方案中，本发明可以改善抗体药代动力学，并且可以防止由于抗体恒定区域中的C-末端缺失导致的均一性丧失。

    Anti-glypican-3 antibody having improved kinetics in plasma
    7.
    发明授权
    Anti-glypican-3 antibody having improved kinetics in plasma 有权
    具有改善血浆动力学的抗磷脂酰肌醇蛋白聚糖-3抗体

    公开(公告)号：US08497355B2

    公开(公告)日：2013-07-30

    申请号：US12733933

    申请日：2008-09-26

    申请人： Tomoyuki Igawa ,  Taichi Kuramochi ,  Hirotake Shiraiwa ,  Hiroyuki Tsunoda ,  Tatsuhiko Tachibana ,  Takahiro Ishiguro

    发明人： Tomoyuki Igawa ,  Taichi Kuramochi ,  Hirotake Shiraiwa ,  Hiroyuki Tsunoda ,  Tatsuhiko Tachibana ,  Takahiro Ishiguro

    IPC分类号： C07K16/30 ,  A61K39/395 ,  C07H21/04 ,  C12P21/08 ,  C12N15/13

    CPC分类号： C07K16/2863 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/18 ,  C07K16/30 ,  C07K16/303 ,  C07K2317/14 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/92 ,  C07K2317/94 ,  C12N15/8258

    摘要： A method of modulating the plasma half-life of anti-glypican 3 antibody, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody that has a plasma half-life that has been modulated, a method of preparing the anti-glypican 3 antibody and a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient are provided. Disclosed is a method of modulating the plasma half-life of anti-glypican 3 antibody by modifying an amino acid residue that is exposed on the surface of the anti-glypican 3 antibody; and anti-glypican 3 antibody that has a plasma half-life that has been modulated by amino acid residue modification, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody, and a method of preparing the anti-glypican 3 antibody and producing a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient.

    摘要翻译： 调节抗磷脂酰肌醇蛋白聚糖3抗体的血浆半衰期的方法，一种药物组合物，其包含具有调节的血浆半衰期的抗磷脂酰肌醇蛋白聚糖3抗体作为活性成分，制备抗磷脂酰肌醇蛋白聚糖的方法 提供了包含抗磷脂酰肌醇蛋白聚糖3抗体作为活性成分的药物组合物。 公开了通过改变暴露于抗磷脂酰肌醇蛋白聚糖3抗体表面的氨基酸残基来调节抗磷脂酰肌醇蛋白聚糖3抗体的血浆半衰期的方法; 和具有通过氨基酸残基修饰调节的血浆半衰期的抗磷脂酰肌醇蛋白聚糖3抗体，包含作为活性成分的磷脂酰肌醇蛋白聚糖3抗体的药物组合物，以及制备抗磷脂酰肌醇蛋白聚糖3抗体的方法和 制备包含抗磷脂酰肌醇蛋白聚糖3抗体作为活性成分的药物组合物。

    ANTI-GLYPICAN-3 ANTIBODY HAVING IMPROVED KINETICS IN PLASMA
    9.
    发明申请
    ANTI-GLYPICAN-3 ANTIBODY HAVING IMPROVED KINETICS IN PLASMA 有权
    具有等离子体改善动力学的抗GLYPICAN-3抗体

    公开(公告)号：US20100239577A1

    公开(公告)日：2010-09-23

    申请号：US12733933

    申请日：2008-09-26

    申请人： Tomoyuki Igawa ,  Taichi Kuramochi ,  Hirotake Shiraiwa ,  Hiroyuki Tsunoda ,  Tatsuhiko Tachibana ,  Takahiro Ishiguro

    发明人： Tomoyuki Igawa ,  Taichi Kuramochi ,  Hirotake Shiraiwa ,  Hiroyuki Tsunoda ,  Tatsuhiko Tachibana ,  Takahiro Ishiguro

    IPC分类号： A61K39/395 ,  C07K16/18 ,  C07H21/00 ,  C12N5/10 ,  C12P21/02 ,  A61P35/00

    CPC分类号： C07K16/2863 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/18 ,  C07K16/30 ,  C07K16/303 ,  C07K2317/14 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/92 ,  C07K2317/94 ,  C12N15/8258

    摘要： A method of modulating the plasma half-life of anti-glypican 3 antibody, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody that has a plasma half-life that has been modulated, a method of preparing the anti-glypican 3 antibody and a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient are provided. Disclosed is a method of modulating the plasma half-life of anti-glypican 3 antibody by modifying an amino acid residue that is exposed on the surface of the anti-glypican 3 antibody; and anti-glypican 3 antibody that has a plasma half-life that has been modulated by amino acid residue modification, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody, and a method of preparing the anti-glypican 3 antibody and producing a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient.

    摘要翻译： 调节抗磷脂酰肌醇蛋白聚糖3抗体的血浆半衰期的方法，一种药物组合物，其包含具有调节的血浆半衰期的抗磷脂酰肌醇蛋白聚糖3抗体作为活性成分，制备抗磷脂酰肌醇蛋白聚糖的方法 提供了包含抗磷脂酰肌醇蛋白聚糖3抗体作为活性成分的药物组合物。 公开了通过改变暴露于抗磷脂酰肌醇蛋白聚糖3抗体表面的氨基酸残基来调节抗磷脂酰肌醇蛋白聚糖3抗体的血浆半衰期的方法; 和具有通过氨基酸残基修饰调节的血浆半衰期的抗磷脂酰肌醇蛋白聚糖3抗体，包含作为活性成分的磷脂酰肌醇蛋白聚糖3抗体的药物组合物，以及制备抗磷脂酰肌醇蛋白聚糖3抗体的方法和 制备包含抗磷脂酰肌醇蛋白聚糖3抗体作为活性成分的药物组合物。

    Antibody constant region variant
    10.
    发明授权
    Antibody constant region variant 有权
    抗体恒定区变体

    公开(公告)号：US09228017B2

    公开(公告)日：2016-01-05

    申请号：US13257112

    申请日：2010-03-19

    申请人： Tomoyuki Igawa ,  Atsuhiko Maeda ,  Hirotake Shiraiwa

    发明人： Tomoyuki Igawa ,  Atsuhiko Maeda ,  Hirotake Shiraiwa

    IPC分类号： C07K16/28

    CPC分类号： C07K16/2866 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94

    摘要： By altering amino acid sequence, the present inventors succeeded in providing constant regions that can confer antibodies with favorable properties, particularly as pharmaceuticals. The variants of the constant regions provided by the present invention will remarkably reduce heterogeneity when applied to antibody production. That is, homogeneity of antibodies can be maintained at a high level by introducing the alterations provided by the present invention into the antibody heavy chain constant regions. More specifically, decrease in homogeneity caused by —SS— bond linkage differences in the heavy chains of antibody molecules can be prevented. Furthermore, in a preferred embodiment of the present invention, pharmacokinetics of antibodies can be improved and decrease in homogeneity caused by deletion of the C terminus in the antibody constant region can be ameliorated.

    摘要翻译： 通过改变氨基酸序列，本发明人成功地提供了可赋予具有良好性质的抗体的恒定区域，特别是作为药物。 当应用于抗体生产时，由本发明提供的恒定区的变体将显着降低异质性。 也就是说，通过将本发明提供的改变引入抗体重链恒定区，可以将抗体的均一性保持在高水平。 更具体地，可以防止由抗体分子的重链中的-SS-键连接差引起的同质性的降低。 此外，在本发明的优选实施方案中，可以改善抗体的药代动力学，并且可以改善由抗体恒定区中的C末端缺失引起的同质性降低。